



LucidQuest Intelligence
Accelerate your success

IAS 2025

13th IAS Conference on
HIV Science

13-17 July 2025
Kigali, Rwanda, and virtually



IAS 2025

aidsmap

Official scientific media partner

AIDS-IAS 2025 Preview – Table of Contents

| | |
|--|--------------|
| • <u>General Overview and Conference Themes</u> | <u>3-5</u> |
| • <u>Noteworthy Scientific presentations at AIDS-IAS'25</u> | <u>6-53</u> |
| • <u>Key Topics From Notable Presentations</u> | <u>7-12</u> |
| • <u>Focus of Key Industry Sponsored Sessions at AIDS-IAS'25</u> | <u>13</u> |
| • <u>Notable Presentations at AIDS-IAS'25</u> | <u>14-51</u> |
| • <u>Key Industry Sponsored Sessions Information</u> | <u>53</u> |
| • <u>Noteworthy AI / ML Presentations</u> | <u>54-67</u> |
| • <u>Key AI / ML Themes</u> | <u>55-58</u> |
| • <u>Key AI/ML Presentations at AIDS-IAS'25</u> | <u>59-67</u> |
| • <u>Get in touch with LucidQuest</u> | <u>68</u> |



AIDS-IAS 2025 – General Overview (1/2)

- ➔ **Global Reach & Scientific Impact:** Over 12,000 participants from 130+ countries are expected to gather, reinforcing AIDS-IAS 2025 as the world's premier platform for HIV science, policy, and implementation
- ➔ **Robust Scientific Program:** More than 150 sessions and 80+ workshops will cover HIV prevention, treatment, cure research, comorbidities, and integrated health systems across global and local contexts
- ➔ **Translational Innovation Across Settings:** The program will emphasize real-world data, community-led trials, and integration of HIV care with SRHR, NCDs, and mental health services in high-burden regions.
- ➔ **Technology and Digital Health Integration:** AI, machine learning, and mHealth innovations will feature prominently, driving transformation in care personalization, surveillance, and patient engagement strategies
- ➔ **Youth, Equity, and Community Leadership:** Key tracks will prioritize youth voices, key population engagement, and gender equity in research design and health delivery models





AIDS-IAS 2025– Conference Themes (1/2)



- **Long-Acting Therapeutics & Delivery Models:** Evidence will focus on the real-world performance of injectable CAB+RPV and lenacapavir, including adherence, safety, and community-led delivery innovations
- **Dual ART & Treatment Optimization:** Studies will support 2-drug regimens (2DR) like DTG/3TC, exploring safety, durability, and outcomes in both naïve and suppressed patients
- **HIV-Associated Comorbidities & Metabolic Health:** Sessions will address weight gain, cardiometabolic risks, and aging with HIV, particularly in relation to INSTI-based regimens and comorbidity burden
- **AI/ML Applications in HIV Care:** AI tools will be presented for predicting ART interruption, improving adherence, risk profiling, and optimizing care using real-time and geospatial analytics
- **HIV Cure Research and Immune Modulation:** ATI trials, bNAb studies, and immune-based strategies will showcase progress toward sustained viral remission and reservoir targeting



AIDS-IAS 2025– Conference Themes (2/2)



- **TB and Opportunistic Infection Integration:** New findings will discuss short-course TB prophylaxis and integrated treatment models for advanced HIV disease and TB co-infection
- **Mental Health and Psychosocial Interventions:** Interventions leveraging digital platforms and peer-led models will showcase impact on mental health outcomes in youth and young adults living with HIV
- **Pediatric and Maternal HIV Advances:** Updated data on ART safety and pharmacokinetics in infants and pregnant women likely to inform future guideline shifts and rollout of long-acting options
- **Implementation and Health Systems Science:** Studies expected to highlight differentiated service delivery, decentralized care, and task-shifting models to improve retention and adherence

Noteworthy Scientific presentations at AIDS-IAS 2025





Key Topics From Notable Presentations (1/6)

✓ • **Antiretroviral Therapy (ART), Drug Trials & Resistance:**

- IAS 2025 will spotlight data from DRAGON, DYAD, DOLCE, VOLITION, SPRINT, RACER, Sungura, and ulonivirine trials, emphasizing comparative effectiveness, long-term safety, and resistance monitoring
- Focus areas include dual versus triple regimens, ART in aging and comorbid populations, lipid and renal outcomes, TB co-infection, and treatment simplification with novel agents like Albuvirtide, informing optimized, patient-centered HIV care strategies

✓ • **Coinfections & Comorbidities (HBV, HPV, COVID-19, Mpox, NCDs):**

- IAS 2025 will feature data from CoVPN Ubuntu, Mpox PROJECT, ELEA-Brasil, LIROH, PRECARIF, and SPRINT, highlighting vaccine responses, PASC, metabolic complications, and cognitive decline in aging PLWH
- Additional studies from Asia-Pacific and Africa will examine organ dysfunction and cytomegalovirus-related mortality, reinforcing the need for integrated HIV, NCD, and long-term care strategies



Key Topics From Notable Presentations (2/6)



- **Gender, Key Populations, Sexual Health & Rights:**

- Presentations will discuss how stigma, violence, and structural barriers increase HIV vulnerability among LGBTQ+, youth, and mobile populations, with evidence from SEATrans, TRANS&VIH, NNHIV, and Rakai studies
- Data from AMP Peru, Adamawa, Sri Lanka, and Argentina will explore gaps in inclusion, provider training, and prevention access, emphasizing rights-based, community-led HIV care approaches.



- **HIV Cure, Vaccine & Broadly Neutralizing Antibody (bNAb) Trials:**

- Spotlight will be on advancements in cure and prevention science through trials like HVTN 097/702, IAVI G003, HVTN 304/307, and PedMAb1, showcasing nanoparticle, DNA, and bNAb-based vaccine platforms
- Cure-focused studies like FRESH, PAUSE, and vesatolimod set to explore ATI models, while CASPR, BRILLIANT, and DigiTaPP are expected to showcase community-driven trial design and digital innovation



Key Topics From Notable Presentations (3/6)

✓ • **HIV Testing and HIV Self-Testing (HIVST):**

- The conference will highlight HIVST scale-up efforts in Zambia, South Africa, and Zimbabwe, and integration with PrEP services in Uganda, Mozambique, and Eswatini for youth and key populations
- Studies from Cameroon, Kenya, and Brazil's A Hora é Agora project will emphasize test validation, linkage strategies, and digital outreach to boost HIVST uptake and engagement

✓ • **Implementation Science & Differentiated Service Delivery:**

- Emphasis will be on how adaptive HIV care models leveraging community leadership, digital platforms, and system reforms can improve long-term outcomes. Data from Mozambique, Zambia, and South Africa set to illustrate how differentiated access and task-shifting boost retention
- The Rudi Kundini Trial, EMMATAC, and Ahana Project will showcase how peer support and youth engagement enhance adherence. Meanwhile, case studies from India, Ukraine, and Vietnam will discuss how private sector involvement, mHealth innovations, and policy integration sustain ART delivery in evolving health systems, underscoring the need for resilient, equity-focused HIV program design



Key Topics From Notable Presentations (4/6)

✓ • **Mental Health, Stigma, and Psychosocial Studies:**

- Experts are expected to discuss mental health burdens in adolescents and key populations, with data from Sauti ya Vijana, IMPAACT 2016, TENDAI, and Positive Perspectives 3 will showcase how stigma, anxiety, and peer-led support impact engagement and outcomes
- Studies from WIHS, Côte d'Ivoire, Malawi, and Nasarawa will emphasize women's health, ART in pregnancy, cervical cancer screening, and pediatric HIV prevention
- Youth-focused research from CIPHER-ADOLA, RaDAR, PrEPUp!, and PURPOSE 1 set to highlight adolescent self-efficacy, stigma resilience, and acceptability of PrEP and vaccine trials in diverse settings

✓ • **Modeling, Policy & Public Health Systems:**

- Spotlight will be on the impact of declining global funding, as shown in SWAGAA, NASA Nigeria, and ANRS 0792, on the HIV program continuity and epidemic control across regions
- Modeling studies from MPYA, PURPOSE, and South Africa will explore PrEP access, cost-effectiveness, and rollout delays, while Brazil, Kenya, and Ukraine case studies will address integration gaps, equity, and policy reform



Key Topics From Notable Presentations (5/6)



• **Pre-Exposure Prophylaxis (PrEP), Long-Acting Agents, and Prevention:**

- Sessions are expected to highlight PrEP access trends across Malawi, Tanzania, Zambia, and the Philippines, showcasing public sector integration, peer-led outreach, and tailored rollout strategies for high-risk groups
- Studies from ImPrEP CAB Brasil, PrEPared to Choose, and TWIST will examine PrEP modality preferences, switching behavior, and gender-affirming care
- Data from South Africa, Uganda, China, and the U.S. will explore adherence, disclosure, and how embedding PrEP in STI and reproductive services enhances continuity and impact



Key Topics From Notable Presentations (6/6)



• **Tuberculosis and HIV/TB Integration:**

- Gaps in integrated TB/HIV diagnosis, with data from Côte d'Ivoire, Mozambique, and Nigeria, will be highlighted, possibly focusing on missed testing opportunities and the value of CD4-based screening tools
- Studies from South Africa, Uganda, and India set to discuss short-course TB prophylaxis, recurrence predictors, and hemoglobin-based risk tools for PLWH with advanced disease
- SaDAPT and the East Africa factorial trial will explore how same-day ART and sepsis-adapted TB therapy can reduce mortality in co-infected individuals, supporting more responsive, integrated treatment strategies



Focus of Key Industry Sponsored Sessions at AIDS-IAS 2025



- **Gilead Sciences:**

- Focus Areas: HIV Prevention Strategies & Long-Acting Therapies in Special Populations
- Sessions will highlight the role of long-acting ARVs in pregnancy, evolving prevention frameworks, and Gilead's leadership in shaping population-specific HIV prevention strategies



- **Merck:**

- Focus Areas: HIV Prevention Clinical Trials & Future-Ready Designs
- Presentations will explore next-generation HIV prevention trial models, adaptive study frameworks, and Merck's contributions to advancing global prevention research pipelines



Notable Presentations And Late-breaking Sessions At AIDS-IAS 2025



Notable Presentations And Late-breaking Sessions

Antiretroviral Therapy (ART), Drug Trials & Resistance (1/4)

| Date | Author | Title |
|--------------|-----------------------|--|
| 14 July 2025 | Chinonyelum Agbo | <u>Safety profile of candidate HIV vaccines across clinical trial phases: a systematic review of global trajectory</u> |
| 14 July 2025 | Chien-Yu Cheng | <u>Week 96 Results from Dolutegravir/lamivudine versus bictegravir/ emtricitabine/tenofovir alafenamide fumarate: Real-world Assessment of weight Gain in people with HIV of Asian Origin (DRAGON)</u> |
| 14 July 2025 | Maria Figueroa | <u>Impact of dual therapy on weight gain and metabolic outcomes in naïve people living with HIV (PLHIV) with CD4 counts <200 cells/mm3: findings from the DOLCE study</u> |
| 14 July 2025 | Ting Huang | <u>Predictors of liver fibrosis in people living with HIV-HBV co-infection on antiretroviral therapy: a long-term observational cohort study</u> |
| 14 July 2025 | John Njegite | <u>Comparative analysis of estimated glomerular filtration rate in people living with HIV on ART in AFRICOS study</u> |
| 14 July 2025 | Bruce Shinga Wembulua | <u>First-line treatment failure in HIV care: insights from a 10-year multicenter observational study of over 6,500 people living with HIV in Senegal</u> |

Notable Presentations And Late-breaking Sessions

Antiretroviral Therapy (ART), Drug Trials & Resistance (2/4)



| Date | Author | Title |
|--------------|-----------------------|---|
| 14 July 2025 | Charlotte-Paige Rolle | <u>Patient-reported outcomes among virally suppressed people living with HIV switching to dolutegravir/lamivudine vs. continuing bictegravir/emtricitabine/tenofovir alafenamide from the randomized DYAD study</u> |
| 14 July 2025 | Ezequiel Cordova | <u>Efficacy of dolutegravir plus lamivudine in treatment-naïve people with HIV with baseline transmitted drug-resistance mutations: a subanalysis of the D2ARLING study</u> |
| 14 July 2025 | Yarong Li | <u>Efficacy, and safety of ainuovirine-based antiretroviral regimen in women with HIV-1: the pooled analysis of the RACER, and SPRINT studies, two multicenter, randomized, active controlled phase 3 trials</u> |
| 14 July 2025 | Jesse Nussbaum | <u>An open-label Phase 1 study to evaluate drug interactions between multiple weekly doses of ulonivirine (MK-8507) and single doses of islatravir in adults without HIV</u> |
| 14 July 2025 | Jesse Nussbaum | <u>A double-blind, placebo-controlled, Phase 1 study to evaluate extended multiple dosing of ulonivirine (MK-8507) in adults without HIV</u> |
| 14 July 2025 | Xinsheng Wu | <u>Comparative effectiveness of modern antiretroviral therapy regimens among people living with HIV in China: a multicenter cohort study</u> |



Notable Presentations And Late-breaking Sessions

Antiretroviral Therapy (ART), Drug Trials & Resistance (3/4)

| Date | Author | Title |
|--------------|-------------------------|---|
| 14 July 2025 | Maria Jesús Perez Elías | <u>Real-world efficacy and tolerability of long-acting cabotegravir/rilpivirine in woman with HIV and polypharmacy plus comorbidities</u> |
| 14 July 2025 | Yinzhong Shen | <u>Double-dose dolutegravir and lamivudine versus efavirenz-based antiretroviral therapy for individuals with HIV and tuberculosis: a multicenter, open-label, randomized trial</u> |
| 14 July 2025 | Mfonobong Umoh | <u>The prevalence and associated factors of potential drug-drug interactions in people living with HIV/AIDS: a retrospective study at a Nigerian tertiary hospital</u> |
| 14 July 2025 | Lin Gan | <u>Safety and efficacy of four-weekly Albuvirtide plus Dolutegravir in virologically suppressed adults living with HIV-1: a pooled analysis based on two prospective studies</u> |
| 14 July 2025 | Saadick Ssentongo | <u>High prevalence of Dolutegravir Resistance and associated factors among people living with HIV with virologic failure in North Eastern Uganda: a retrospective study (2022–2024)</u> |
| 15 July 2025 | Xinming Yun | <u>Favorable lipid profile in people with HIV-1 switching to ainoovirine-based antiretroviral regimen: week 96 results from SPRINT, a randomized phase 3 trial</u> |



Notable Presentations And Late-breaking Sessions

Antiretroviral Therapy (ART), Drug Trials & Resistance (4/4)

| Date | Author | Title |
|--------------|----------------------|--|
| 15 July 2025 | Loice Achieng Ombajo | <u>Is exclusion of tenofovir from antiretroviral regimens safe in Africa: insights on hepatitis B from the switch to DTG/3TC (Sungura) study</u> |
| 15 July 2025 | Loice Achieng Ombajo | <u>Efficacy and safety of switching to dolutegravir/lamivudine dual therapy from bictegravir/emtricitabine/tenofovir alafenamide among virally suppressed older adults ≥60 years: week 24 results from the Sungura study</u> |
| 15 July 2025 | John KOETHE | <u>A5391: a randomized multicenter 3-arm controlled trial for people with obesity on integrase inhibitors and tenofovir alafenamide switching to doravirine, with or without tenofovir disoproxil fumarate (The DO-IT Trial)</u> |
| 16 July 2025 | Cristina Mussini | <u>Risk of developing low-level viremia (LLV) among people with HIV (PWH) with current HIV-RNA≤50 copies/mL receiving 2DR vs 3DR: a case control study</u> |
| 16 July 2025 | Bryn Jones | <u>Rapid virologic suppression with DTG/3TC facilitates early switch to CAB+RPV LA for treatment-naïve people living with HIV: suppression phase outcomes from the Phase 3b VOLITION study</u> |
| 16 July 2025 | Hong Qin | <u>Safety and efficacy of ANV/3TC/TDF vs E/C/F/TAF for maintaining virologic suppression in adults living with HIV-1: week 96 results from the phase 3, noninferiority SPRINT randomized trial</u> |

Notable Presentations And Late-breaking Sessions

Coinfections & Comorbidities (HBV, HPV, COVID-19, Mpox, NCDs) (1/4)



| Date | Author | Title |
|--------------|--------------------------|---|
| 14 July 2025 | Evelyn Yayra Afua Bonney | <u>Efficacy of COVID-19 vaccines and immune responses in people living with HIV In Ghana</u> |
| 14 July 2025 | Fernand Rwamwejo | <u>Prevalence and determinants of post-acute sequelae of SARS-CoV-2 (PASC) among people living with HIV in Rwanda: a cross-sectional study</u> |
| 14 July 2025 | Jayne Ellis | <u>Cytomegalovirus viraemia is strongly associated with 6-month mortality amongst adults living with advanced HIV disease: a prospective cohort study in South Africa</u> |
| 14 July 2025 | Xinsheng Wu | <u>Genetic insights into HIV-1 and risks of COVID-19 susceptibility, hospitalization and severity: a Mendelian randomisation study</u> |
| 14 July 2025 | Alida Ngwije | <u>Impact of interventions to prevent mother-to-child transmission of hepatitis B virus in Rwanda: a modelling study</u> |
| 14 July 2025 | Margaret Lartey | <u>Normalization of inflammatory bio-markers post dolutegravir initiation among a cohort of persons living with HIV in Accra, Ghana: a prospective study</u> |

Notable Presentations And Late-breaking Sessions

Coinfections & Comorbidities (HBV, HPV, COVID-19, Mpox, NCDs) (2/4)



| Date | Author | Title |
|--------------|-------------------------|---|
| 14 July 2025 | Thiago Silva Torres | <u>Mpox diagnosis and vaccination among gay and other men who have sex with men and transgender women in Brazil: results from a large nationwide online survey</u> |
| 15 July 2025 | Veronique Carmen Bailey | <u>Pregnancy outcomes in the multicentre CoVPN 3008 (Ubuntu) COVID-19 vaccine trial among people with HIV in East and Southern Africa</u> |
| 15 July 2025 | Napon Hiranburana | <u>Lipoprotein(a) and De Novo coronary artery calcification in aging Thai PLWH: A six-year study</u> |
| 15 July 2025 | Jen Manne-Goehler | <u>Liraglutide for obesity in HIV (LIROH): a clinical trial evaluating acceptability, impact on cardiometabolic risks & gut immunity of GLP-1 receptor agonists in South Africa</u> |
| 15 July 2025 | Thinh Toan Vu | <u>Kidney dysfunction in adults living with HIV and HBV: a 10-year retrospective cohort study across seven Asia-Pacific countries</u> |
| 15 July 2025 | Nooliet Kabanyana | <u>Comparative study on substance use and HIV risk among PWUD/PWID in the city of Kigali</u> |

Notable Presentations And Late-breaking Sessions

Coinfections & Comorbidities (HBV, HPV, COVID-19, Mpox, NCDs) (3/4)



| Date | Author | Title |
|--------------|---------------------------------|---|
| 15 July 2025 | Jamile Ballivian | <u>Safety, efficacy, and immunogenicity of mpox vaccines: a living systematic review and meta-analysis</u> |
| 15 July 2025 | Mireille Ngale | <u>Safety profile of tecovirimat in Congolese mpox patients enrolled in a randomized controlled trial</u> |
| 15 July 2025 | Karen Aranza Marañon Solorio | <u>Healthcare seeking for mpox: results of an electronic survey among MSM in Mexico City</u> |
| 16 July 2025 | Ting-Wei Huang | <u>Impact of vaccination amid armed conflict on the mpox epidemic in the democratic republic of the Congo, 2024–2025: a modeling study</u> |
| 17 July 2025 | Zeyad KHALIL | <u>PROJECT trial: proactive regional orthopox genomic epidemiology and cross-regional outbreak tracking—a multinational investigation into mpox evolution, vaccine efficacy, and transmission dynamics across the Middle East</u> |
| 17 July 2025 | Cécile HERATE | <u>Efficacy of modified-vaccinia Ankara vaccine as pre-exposure and post-exposure prophylaxis against monkeypox sexual transmission in non-human primate model</u> |

Notable Presentations And Late-breaking Sessions

Coinfections & Comorbidities (HBV, HPV, COVID-19, Mpox, NCDs) (4/4)



| Date | Author | Title |
|--------------|---------------------|--|
| 17 July 2025 | Rodrigo C. Moreira | <u>Association between cognitive performance and subclinical atherosclerosis among older adults with HIV: a cross-sectional evaluation from ELEA-Brasil Study</u> |
| 17 July 2025 | Hong Qin | <u>Profiles of body weight, glucose, and uric acid in PWH on a nucleos(t)ide-based antiretroviral regimen: week 96 results from SPRINT, a randomized phase 3 trial</u> |
| 17 July 2025 | Maria Figueroa | <u>The impact of immune reconstitution inflammatory syndrome (IRIS) in HIV-positive people with CD4 <200 Cells/mm³ Initiating dolutegravir/lamivudine dual therapy: DOLCE study findings</u> |
| 17 July 2025 | Peter James Elyanu | <u>Neutralizing antibody titers are immune correlates of COVID-19 risk in the Ubuntu study of people with HIV in East and Southern Africa</u> |
| 17 July 2025 | Moshao Amos Makhele | <u>Cardiovascular risk profiles and signs of vascular damage in people living with HIV on ART in rural Lesotho: findings from the PRECARIF study</u> |

Notable Presentations And Late-breaking Sessions

Gender, Key Populations, Sexual Health & Rights (1/3)



| Date | Author | Title |
|--------------|-----------------------|---|
| 14 July 2025 | Debbie Malden | <u>Orphanhood and HIV risk among adolescents and young adults in Rakai, Uganda: a prospective cohort study, 1998-2022</u> |
| 14 July 2025 | Ariyaratne Manathunge | <u>Exploring barriers to inclusive care: knowledge gaps and training needs of Sri Lankan government doctors in LGBTIQ health – a cross-sectional study</u> |
| 14 July 2025 | David Chilongozi | <u>"Do people who inject drugs exist in Malawi?": a study to inform the National AIDS Commission's response</u> |
| 14 July 2025 | Kalonde Malama | <u>Identifying the most-at-risk sub-populations for low HIV testing uptake among adolescent boys and young men: results from a nationally representative survey in Zambia</u> |
| 14 July 2025 | Marguerite Thorp | <u>Understanding mobility and interruption in HIV treatment differences by gender in Malawi: a case-control study</u> |
| 14 July 2025 | Tanabodee Payuha | <u>HIV sexual risk, stigma, mental health, and substance use among transgender people in Southeast Asia: the SEATrans study</u> |

Notable Presentations And Late-breaking Sessions

Gender, Key Populations, Sexual Health & Rights (2/3)



| Date | Author | Title |
|--------------|------------------------|--|
| 14 July 2025 | Mamaswatsi Kopeka | <u>Bridging barriers to HIV/SRH healthcare for young women in Lesotho through hair salons: a qualitative acceptability and feasibility study</u> |
| 14 July 2025 | Hao Zhang | <u>The association between social determinants of health and HIV risk behaviors and HIV testing among sexual and gender minority individuals: a national survey study</u> |
| 14 July 2025 | Hugo Sánchez Sarmiento | <u>Facilitating transgender participation in efficacy trials – mixed methods study at HVTN clinical research sites in Peru conducting the Antibody Mediated Prevention Study (AMP)</u> |
| 14 July 2025 | Adek Bassey | <u>Engaging displaced girls as leaders in HIV conversations and Sexual and Reproductive Health and Rights (SRHR): a case study from Adamawa State, Nigeria</u> |
| 14 July 2025 | Melonie Walcott | <u>Patient-provider relationship and engagement in HIV care: perspectives of Black men who have sex with men (BMSM) in the NNHIV cohort study</u> |
| 14 July 2025 | Xinyi Li | <u>Depressive disorder, HIV testing, and high-risk behaviors among transgender persons in a US national study</u> |

Notable Presentations And Late-breaking Sessions

Gender, Key Populations, Sexual Health & Rights (3/3)



| Date | Author | Title |
|--------------|----------------------|---|
| 15 July 2025 | Jean Jacques Irakiza | <u>Exploring gender disparities in viral load suppression among people with HIV: insights from a cohort study at the University Teaching Hospital of Kigali</u> |
| 16 July 2025 | Ines ARISTEGUI | <u>Community-based participatory research analysis with transgender individuals as peer research associates in a qualitative study on female sex workers' health and rights in Argentina</u> |
| 17 July 2025 | Marion FIORENTINO | <u>HIV transmission risk, sexual and mobility behaviors among men, women, and female sex workers living with HIV in informal gold mining sites in Mali: the ANRS-12392 – Sanu Gundo study</u> |
| 17 July 2025 | Brian Minalga | <u>TGD scorecard: addressing trans erasure in HIV clinical trials</u> |
| 17 July 2025 | Christopher Ferraris | <u>Intimate partner violence and determinants of HIV seroconversion among female caregivers in KwaZulu-Natal, South Africa: insights from the Asenze Cohort longitudinal study</u> |
| 17 July 2025 | Marion FIORENTINO | <u>Exposure to violence among transgender women living with HIV in France, engaged or not in sex work: results from the national ANRS-14056 TRANS&VIH study</u> |



Notable Presentations And Late-breaking Sessions

HIV Cure, Vaccine & Broadly Neutralizing Antibody (bNAb) Trials (1/3)

| Date | Author | Title |
|--------------|--------------------------------|--|
| 13 July 2025 | Glenda GRAY | HVTN 097 leading to HVTN 702 Trial |
| 13 July 2025 | Nyaradzo Mavis MGODI | The AMP trial |
| 13 July 2025 | Julien NYOMBAYIRE MUTAGISHA | The importance of discovery trials to accelerate HIV vaccine research – IAVI G003 |
| 13 July 2025 | Nyaradzo Mavis MGODI | Panel discussion & interactive Q&A: HIV vaccine trials in Africa: Challenges, lessons and next steps |
| 13 July 2025 | Krista DONG | Implementing the first ATI-inclusive HIV cure trial in Africa: lessons from the FRESH cohort |
| 14 July 2025 | Venkatesan Chakrapani | Preferences for future HIV vaccines among key populations in India: findings from the DigiTaPP Choice Experiment Study |

Notable Presentations And Late-breaking Sessions

HIV Cure, Vaccine & Broadly Neutralizing Antibody (bNAb) Trials (2/3)



| Date | Author | Title |
|--------------|------------------|--|
| 14 July 2025 | Simone Hendricks | <u>Designing a safety monitoring system for BRILLIANT consortium-led HIV vaccine trials in Africa</u> |
| 14 July 2025 | Grace Kumwenda | <u>Enhancing community engagement in HIV prevention clinical trial design: insights from CASPR's Clinical Trial Design Academy</u> |
| 14 July 2025 | Sung-Hsi Huang | <u>Exploring HIV care disparities among foreigners in Taiwan: insights from a multicenter study (2017–2023)</u> |
| 14 July 2025 | Wezzie Dunda | <u>HIV vaccine trial experiences: lessons for upcoming HIV, gonorrhea and chlamydia vaccine research</u> |
| 15 July 2025 | Shirley COLLIE | <u>AI in action: How a South African health-tech company is transforming HIV vaccine trials</u> |
| 16 July 2025 | Adrienne SHAPIRO | <u>HVTN 307: phase 1 clinical trial of a ferritin nanoparticle preventive HIV vaccine with different adjuvants to induce HIV-1 Env V3-glycan-specific broadly neutralizing antibody precursors</u> |



Notable Presentations And Late-breaking Sessions

HIV Cure, Vaccine & Broadly Neutralizing Antibody (bNAb) Trials (3/3)

| Date | Author | Title |
|--------------|---------------------|---|
| 16 July 2025 | Gabriella SCARLATTI | <u>PedMAB1 trial: safety of two broadly neutralising antibodies, CAP256V2LS and VRC07-523LS, administered singly or concurrently at birth and 3 months to breastfeeding HIV-1 exposed neonates and infants born without HIV</u> |
| 16 July 2025 | Devi SenGupta | <u>Vesatolimod pharmacodynamic responses in a trial of vesatolimod and broadly neutralizing antibodies in early-treated South African women with clade C HIV-1</u> |
| 16 July 2025 | Ronnie M. Gravett | <u>Safety and immunogenicity of vaccination with a synthetic DNA encoding native-like trimer alone and boosted with Env trimer 4571 for prevention of HIV-1: results from HVTN 304</u> |
| 17 July 2025 | Mina HOSSEINIPOUR | <u>bNAb immunotherapy and HIV remission: Insights from the PAUSE (Pausing Antiretroviral Treatment Under Structured Evaluation) trial</u> |
| 17 July 2025 | Joyeeta MUKHERJEE | <u>"Superbees Awakened" - development of a digital game to enhance understanding of germline-targeting vaccine trials among communities and site staff in South Africa and India</u> |

Notable Presentations And Late-breaking Sessions

HIV Testing and HIV Self-Testing (HIVST) (1/2)



| Date | Author | Title |
|--------------|-----------------------------|--|
| 13 July 2025 | Karin HATZOLD | <u>Insights from HIVST implementation following WHO guidance: Case study Zambia</u> |
| 13 July 2025 | Alarice MARSH | <u>Insights from HIVST implementation following WHO guidance: Case study South Africa</u> |
| 13 July 2025 | Getrude NCUBE | <u>Insights from HIVST implementation following WHO guidance: Case study Zimbabwe</u> |
| 13 July 2025 | Thato CHIDARIKIRE | <u>Share early lessons from integrating HIVST for oral PrEP initiation and continuation: Case study Uganda</u> |
| 13 July 2025 | Guita AMANE | <u>Share early lessons from integrating HIVST for oral PrEP initiation and continuation: Case study Mozambique</u> |
| 13 July 2025 | Lenhle Philile NSIBANDZE | <u>Share early lessons from integrating HIVST for oral PrEP initiation and continuation: Case study Eswatini</u> |

Notable Presentations And Late-breaking Sessions

HIV Testing and HIV Self-Testing (HIVST) (2/2)



| Date | Author | Title |
|--------------|------------------------|---|
| 14 July 2025 | Jean de Dieu Anoubissi | <u>Evaluation of eight HIV rapid test kits: findings from the verification study conducted in Cameroon</u> |
| 14 July 2025 | Micheal Segawa | <u>Perceptions, acceptability, and utilization of HIV self-testing kits among young people in urban slums in Kampala: a mixed methods study</u> |
| 14 July 2025 | Paulo Nery | <u>Enhancing communication strategies to promote HIV self-testing through social media: an exploratory study of the 'A Hora é Agora' project in five Brazilian Municipalities, 2024</u> |
| 15 July 2025 | Ronald Olum | <u>Acceptability and feasibility of HIV self-testing among adolescent girls and young women in rural Northern Uganda: a baseline formative study</u> |
| 17 July 2025 | Holly Nishimura | <u>Motivations for linkage to HIV services after HIV self-testing among fishermen in Kenya: a qualitative study</u> |

Notable Presentations And Late-breaking Sessions

Implementation Science & Differentiated Service Delivery (1/5)



| Date | Author | Title |
|--------------|----------------|---|
| 14 July 2025 | Ezekiel Luoga | <u>Stigma-directed intervention to improve linkage to HIV care for people living with HIV in Rural Tanzania: a pre-post implementation study</u> |
| 14 July 2025 | Peter Maiya | <u>Evaluation of characteristics and clinical outcomes in advanced HIV disease patients: insights from the USAID Fahari ya Jamii Project – a retrospective study</u> |
| 14 July 2025 | Joachim Kato | <u>Early sexual debut and HIV sero-prevalence among adult females (18-50 years): evidence from a rural and urban longitudinal cohort study in Uganda</u> |
| 14 July 2025 | Nikita Saß | <u>The effect of same-day HIV treatment initiation (SDI) on one-year outcomes in low- and middle-income countries: systematic review and meta-analysis of randomised trials</u> |
| 14 July 2025 | Andwayne Davis | <u>The community treatment observatory: pilot phase in Western Jamaica</u> |
| 14 July 2025 | Oliver Mweemba | <u>Re-organizing clinical processes, workflow and task-shifting to integrate HIV and NCD care: results of a formative mixed methods evaluation in Lusaka, Zambia</u> |

Notable Presentations And Late-breaking Sessions

Implementation Science & Differentiated Service Delivery (2/5)



| Date | Author | Title |
|--------------|----------------------|--|
| 14 July 2025 | Kelvin Balakasi | <u>Clients experiences following an economic shock in Malawi: a descriptive cross-sectional study</u> |
| 14 July 2025 | Dorian Ho | <u>Youth leadership and engagement in HIV strategy and policy development: a case study from the UNICEF/WHO/UNAIDS Blueprint Collaborative</u> |
| 14 July 2025 | Paul Nyasulu | <u>Enhanced index testing process improves HIV case identification among index contacts: case study for Mponela Rural Hospital, Dowa, Malawi</u> |
| 14 July 2025 | Wezi Mutambo | <u>Enhancing viral load suppression and disclosure rates through multidisciplinary case conferences in Eastern Province, Zambia: a retrospective study</u> |
| 14 July 2025 | Kwena Rayneth Tlhaku | <u>Referral to differentiated antiretroviral therapy delivery at 6 months after initiation: a retrospective cohort study in KwaZulu-Natal, South Africa</u> |
| 14 July 2025 | Caroline De Schacht | <u>Increased retention in care among persons with HIV receiving health facility-based HIV care outside of normal working hours in central Mozambique: a retrospective cohort study (2021-2024)</u> |



Notable Presentations And Late-breaking Sessions

Implementation Science & Differentiated Service Delivery (3/5)



| Date | Author | Title |
|--------------|----------------------|---|
| 14 July 2025 | Rachel Burdon | <u>An audit of antiretroviral regimens in people living with HIV attending a sexual health clinic in Sydney's Inner West in response to the REPRIEVE study</u> |
| 14 July 2025 | Nyawira Gitahi | <u>Enhanced m-health mental health screening for adolescents living with HIV transitioning into adult care (EMMATAC Study)</u> |
| 14 July 2025 | Sireesha Perabathina | <u>Understanding and expanding the role of private health insurance in improving affordable healthcare access for people living with HIV: a case study from India</u> |
| 14 July 2025 | Lokesh Rathore | <u>Partnership in action: how Ahana Project boosted HIV testing through private sector involvement in PMTCT intervention in 13 states of India. Results from Ahana Project supported by GFATM</u> |
| 14 July 2025 | Huong Thu Thi Phan | <u>Labor landscaping: HIV workforce and training needs - insights from a cross-sectional study in Vietnam</u> |
| 14 July 2025 | Rogers Nsubuga | <u>Leveraging routine health facility data for HIV research in refugee settlements: a focus on data quality and insights beyond randomized trials</u> |

Notable Presentations And Late-breaking Sessions

Implementation Science & Differentiated Service Delivery (4/5)



| Date | Author | Title |
|--------------|---------------------|---|
| 14 July 2025 | Katelyn M. Sileo | <u>Factors affecting the provision of client-centered HIV care in central Uganda: a qualitative study with HIV care providers, staff, and community partners</u> |
| 14 July 2025 | Caroline A. Bulstra | <u>Integration of healthcare services for HIV and non-communicable diseases in sub-Saharan Africa: a scoping review of randomized controlled trials and protocols</u> |
| 15 July 2025 | Olena Samsonova | <u>Rate of ART initiation in Ukraine under conditions of critical load on the health care system: results of a retrospective analysis of data from the electronic medical system MSSD</u> |
| 15 July 2025 | Lipin Lukose | <u>Population-level coverage and correlates of enrollment in community-based antiretroviral therapy (ART) refill models in Africa: a multi-country study</u> |
| 15 July 2025 | Esther Nwanja | <u>A peer support approach to client management is not inferior to traditional case management: a study among young persons living with HIV in Nigeria</u> |
| 15 July 2025 | Matilda Mlowe | <u>Can a one-time economic incentive enhance the effectiveness of community-based tracing to re-engage people who have disengaged from HIV care? Rudi Kundini: a cluster randomized trial in Tanzania</u> |

Notable Presentations And Late-breaking Sessions

Implementation Science & Differentiated Service Delivery (5/5)



| Date | Author | Title |
|--------------|-----------------|--|
| 16 July 2025 | Eugene Ruzagira | <u>Mobile men: a key population requiring targeted HIV prevention efforts – insights from the Mobile Men trial in Uganda and South Africa</u> |
| 16 July 2025 | Ellen Brazier | <u>Trends in ART medication adherence support and monitoring across IeDEA sites: results from three waves of consortium-wide site assessment surveys, 2017, 2020, and 2023</u> |

Notable Presentations And Late-breaking Sessions

Mental Health, Stigma, and Psychosocial Studies (1/7)



| Date | Author | Title |
|--------------|-------------------|---|
| 14 July 2025 | Emmanuel Esara | <u>Cervical cancer screening among women living with HIV accessing ART in Northeastern Nigeria: a descriptive study</u> |
| 14 July 2025 | Melissa Senne | <u>Common HPV high-risk types at the Rustenburg CRS during the INSIGHT TRIAL</u> |
| 14 July 2025 | Vincent Ganu | <u>Depressive symptoms among adolescents and young adults living with HIV on antiretroviral therapy: outcomes from a cross-sectional study in Accra, Ghana</u> |
| 14 July 2025 | Angella Masano | <u>Pregnancy and health outcomes among women living with HIV on different antiretroviral therapy in Malawi: a cohort study</u> |
| 14 July 2025 | Elizabeth Senkoro | <u>The relationship of stigma on self-efficacy among adolescents and young adults with HIV enrolled in the Sauti ya Vijana Clinical Trial in Tanzania</u> |
| 14 July 2025 | Yagai Bouba | <u>Diving into the life of Cameroonian adolescents living with HIV/AIDS and their interest for long-acting antiretroviral treatment: evidence from the CIPHER-ADOLA study</u> |

Notable Presentations And Late-breaking Sessions

Mental Health, Stigma, and Psychosocial Studies (2/7)



| Date | Author | Title |
|--------------|----------------------------|--|
| 14 July 2025 | Kalambayi Francois Lumbala | <u>Prevalence and determinants of depressive symptoms among key population on ART at Gobabis Walvis Bay Corridor Group (WBCG) clinic, in Omaheke region - Namibia. A cross-sectional prospective study</u> |
| 14 July 2025 | Arnaud Godin | <u>Evaluating social support, psychological distress, and HIV-related stigma in a cohort of ART-experienced migrant adults living with HIV switched to B/F/TAF in Montreal, Canada – the ASAP-Switch Study</u> |
| 14 July 2025 | Mardge H. Cohen | <u>Achieving high 25-year retention in women’s HIV research: Chicago Women’s Interagency HIV Study (WIHS)</u> |
| 14 July 2025 | Ndinda Christian | <u>Assessing the impact of maternal art adherence and associated factors on perinatal HIV outcomes: a retrospective study in Rwanda (2016-2021)</u> |
| 14 July 2025 | Simon Boni | <u>Human papillomavirus (HPV) vaccination uptake among adolescent girls living with HIV (AGLHIV) in Cote d’Ivoire: a national multi-center study</u> |
| 14 July 2025 | Ethel Wanjiku | <u>Childhood immunization uptake in children of female sex workers: a Nairobi, Kenya study</u> |

Notable Presentations And Late-breaking Sessions

Mental Health, Stigma, and Psychosocial Studies (3/7)



| Date | Author | Title |
|--------------|--------------------------|---|
| 14 July 2025 | Felix K. Rubuga | <u>Factors associated with anxiety among adolescents and young adults living with HIV in Rwanda: a cross-sectional study</u> |
| 14 July 2025 | Nneka Nwokolo | <u>Data from the Positive Perspectives 3 Study highlights the continued need for expansion of awareness, belief and confidence in undetectable equals untransmittable (U=U)</u> |
| 14 July 2025 | Rickesh Patel | <u>Joint patient-provider decision making was associated with improvements in quality of life, adherence and treatment satisfaction for people living with HIV in the Positive Perspectives 3 study</u> |
| 14 July 2025 | Tigest Fisseha Mekonnen | <u>Exploring changes in stigma and its impact on People Living with HIV in Addis Ababa: a qualitative study</u> |
| 14 July 2025 | Safaet Hossain Sujan | <u>Assessment of anxiety and depressive symptoms among gay, bisexual, and other men who have sex with men in Nepal: findings from a cross-sectional study</u> |
| 14 July 2025 | Hrishikesh Sathyamoorthy | <u>Empowering adolescents with perinatally acquired HIV: exploring Self-Efficacy for Exercise (SEE) and its impact on physical activity engagement</u> |

Notable Presentations And Late-breaking Sessions

Mental Health, Stigma, and Psychosocial Studies (4/7)



| Date | Author | Title |
|--------------|---------------------------|---|
| 14 July 2025 | Getrud Joseph Mollel | <u>Symptoms of depression, anxiety, and post-traumatic stress among adolescents and young adults living with HIV at enrollment in the Sauti ya Vijana randomized clinical trial in Tanzania</u> |
| 14 July 2025 | Bulelwa Phumlile Makhutha | <u>Depression and HIV-related self-efficacy among people with TB/HIV initiating TB treatment who were recently diagnosed with HIV versus those who already knew their HIV status</u> |
| 14 July 2025 | Alex Siu WIng Chan | <u>Exploring the role of digital health services in supporting mental health and well-being among ageing people living with HIV in Hong Kong: a qualitative study</u> |
| 14 July 2025 | Arnold Junior Sadio | <u>Enhancing pediatric HIV screening coverage in Côte d'Ivoire and Togo: preliminary results from an intervention led by community associations - The RaDAR project</u> |
| 15 July 2025 | Dorothy Dow | <u>High levels of mental distress among youth with HIV in southern Africa: a description of enrollment into IMPAACT 2016, a randomized controlled trial of a peer-led, group-based mental health intervention</u> |
| 15 July 2025 | Tisungane Mvalo | <u>Empirical treatment against tuberculosis in infants with HIV-associated pneumonia: a multicenter, open label, randomized factorial clinical trial</u> |

Notable Presentations And Late-breaking Sessions

Mental Health, Stigma, and Psychosocial Studies (5/7)



| Date | Author | Title |
|--------------|-------------------|--|
| 15 July 2025 | Charles Ssekyewa | <u>Acceptability and experiences of adolescent girls and young women with genital sampling procedures in an HIV vaccine preparedness study in Uganda</u> |
| 15 July 2025 | Diana Kisamo | <u>Efficacy testing of a stigma reduction intervention clinical trial among urban and rural women with HIV</u> |
| 15 July 2025 | Marguerite Curtis | <u>A community-engaged social media campaign addressing HIV-related stigma in Peru: results from the "DiME" campaign</u> |
| 15 July 2025 | Charné Petinger | <u>"I'm not ready to go back to the clinic": a photovoice study exploring the perceptions and apprehension of ALHIV to transition to adult care at a supportive transition facility</u> |
| 15 July 2025 | Krista L. Dong | <u>Psychological impact of analytical treatment interruption on young women enrolled in an HIV cure-related trial in Durban, South Africa</u> |
| 15 July 2025 | Lydia EFOBI | <u>The double burden: a cross-sectional study of the intersection between mental health and access to HIV Prevention services for female sex workers in internally displaced camps in Calabar, Nigeria</u> |

Notable Presentations And Late-breaking Sessions

Mental Health, Stigma, and Psychosocial Studies (6/7)



| Date | Author | Title |
|--------------|--------------------------|--|
| 15 July 2025 | Concilia BERE | <u>Effectiveness of the TENDAI integrated therapy for depression and adherence to HIV medication delivered by lay adherence counsellors in Zimbabwe: results from a randomized controlled trial.</u> |
| 15 July 2025 | Kathleen WEBER | <u>Prevalence and correlates of sleep apnea using WatchPAT™: Chicago Women's Interagency HIV Study (WIHS)</u> |
| 16 July 2025 | Rickesh Patel | <u>Treatment satisfaction was linked to improved adherence, and mental, physical, sexual and overall health among people living with HIV in the Positive Perspectives 3 study</u> |
| 16 July 2025 | Rehema Maro | <u>Understanding depression among adolescents living with HIV in Tanzania: a mixed-methods study using the think-aloud approach</u> |
| 16 July 2025 | Suzike MUHEYA LIKUMBO | <u>Enhancing PrEP uptake through stigma reduction: results from the PrEPUp! quality improvement collaborative in Malawi</u> |
| 17 July 2025 | Linda-Gail BEKKER | <u>Inclusion of pregnant and lactating people in the PURPOSE 1 study: efficacy, safety, and pharmacokinetics</u> |

Notable Presentations And Late-breaking Sessions

Mental Health, Stigma, and Psychosocial Studies (7/7)



| Date | Author | Title |
|--------------|-----------------------|---|
| 17 July 2025 | Faith Audu | <u>Cervical cancer screening and treatment outcomes in Women living with HIV: a cross-sectional study in Nasarawa State, Nigeria</u> |
| 17 July 2025 | Elizabeth Helena Roos | <u>Prevalence and incidence of chlamydia and gonorrhoea infections in adolescent females using long acting injectable cabotegravir as HIV pre-exposure prophylaxis in South Africa, Zimbabwe and Uganda: results from HPTN 084-01</u> |
| 17 July 2025 | Melanie Amna Abas | <u>Co-existing depression and post-traumatic stress disorders in people living with HIV in Zimbabwe – a mixed-methods study</u> |
| 17 July 2025 | Gaspar CANEPA | <u>Impact of AGT103-T on the HIV proviral reservoir: insights from a modified IPDA in a phase 1 study</u> |

Notable Presentations And Late-breaking Sessions

Modeling, Policy & Public Health Systems (1/3)



| Date | Author | Title |
|--------------|--------------------|--|
| 13 July 2025 | Nonhlanhla DLAMINI | <u>How global funding cuts have directly impacted programmes: SWAGAA case study</u> |
| 14 July 2025 | Ikechukwuka Abah | <u>Demographic and geographic disparities in the prevalence of advanced HIV disease among newly diagnosed people living with HIV in Nigeria: a cross-sectional study across sixteen states</u> |
| 14 July 2025 | Uduak Akpan | <u>Evolving patterns of mortality causes and associated factors among people living with HIV (PLHIV) with unsuppressed viremia in Southern Nigeria: a retrospective cross-sectional study</u> |
| 14 July 2025 | Jessica Haberer | <u>Understanding the impact of PrEP adherence on HIV incidence through community-level drug concentrations: mathematical modeling analysis of the Monitoring PrEP in Young Adult women (MPYA) study in western Kenya</u> |
| 14 July 2025 | Edinah Mudimu | <u>How will delays in the scale-up of long-acting HIV pre-exposure prophylaxis impact health benefits and cost-effectiveness in South Africa? A mathematical modeling study</u> |
| 14 July 2025 | Matthew Kavanagh | <u>PrEP policy in a long acting era: a policy barrier study of 179 countries</u> |

Notable Presentations And Late-breaking Sessions

Modeling, Policy & Public Health Systems (2/3)



| Date | Author | Title |
|--------------|-------------------|--|
| 14 July 2025 | Matthew Kavanagh | <u>Unlocking access to long-acting HIV medications: a 194 country study of compulsory licensing</u> |
| 14 July 2025 | Yasmin Dunkley | <u>AIDS or advanced HIV disease? Results from a multi-stakeholder global DELPHI process to gain consensus on terminology</u> |
| 15 July 2025 | Zeyad Khalil | <u>PHOENIX Trial: Predictive host omics and epidemiologic networks for integrated exit from HIV Transmission in MENA</u> |
| 16 July 2025 | Daniel Citron | <u>Cost-effectiveness and impact of depression treatment implementation on HIV outcomes in western Kenya: a mathematical modeling study</u> |
| 16 July 2025 | Ukawa Sylvester | <u>NASA study on HIV sustainability in Nigeria: funding dependence, challenges, and pathways for long-term solutions</u> |
| 16 July 2025 | Benjamin Bavinton | <u>Predictors and reasons for remaining unvaccinated against mpox in Australia in 2024: results from a prospective observational mixed methods study (2022–2024)</u> |



Notable Presentations And Late-breaking Sessions

Modeling, Policy & Public Health Systems (3/3)



| Date | Author | Title |
|--------------|----------------|---|
| 16 July 2025 | NA | Decoding integration: Country case study Brazil |
| 17 July 2025 | Colleen KELLEY | Estimation of the counterfactual HIV incidence in the PURPOSE trials |
| 17 July 2025 | Romain SILHOL | Modelling the potential detrimental impact of ongoing US government financial support withdrawals on HIV in Western Africa (ANRS 0792): preliminary results |

Notable Presentations And Late-breaking Sessions

Pre-Exposure Prophylaxis, Long-Acting Agents, and Prevention (1/4)



| Date | Author | Title |
|--------------|-----------------------|--|
| 14 July 2025 | Idah Mokhele | <u>PrEP offer and uptake among HIV-negative testers in public primary health care facilities in Malawi: a cross-sectional study</u> |
| 14 July 2025 | Wigilya P. Mikomangwa | <u>Long-term retention in facility-based HIV pre-exposure prophylaxis services among female sex workers in Tanga, Tanzania: a prospective cohort study</u> |
| 14 July 2025 | Fatima Abegail Cholo | <u>Experiences of disclosure of oral pre-exposure prophylaxis (PrEP) and dapivirine vaginal ring use among South African women using PrEP: a qualitative study</u> |
| 14 July 2025 | Anita Kabarambi | <u>The influence of self-efficacy, knowledge, and attitudes on PrEP adherence among women engaged in sex work in Southwestern Uganda</u> |
| 14 July 2025 | Benilde Bepouka | <u>Factors influencing PrEP adherence among female sex workers (FSWs) in Kinshasa, Democratic Republic of Congo: a longitudinal, mixed-methods cohort study</u> |
| 14 July 2025 | Miranda Hope Diaz | <u>Changes in product use perceptions during a crossover study utilising placebo long-acting Pre-exposure Prophylaxis (LA-PrEP) injections and implants for HIV-prevention among South African men</u> |

Notable Presentations And Late-breaking Sessions

Pre-Exposure Prophylaxis, Long-Acting Agents, and Prevention (2/4)



| Date | Author | Title |
|--------------|-----------------------|---|
| 14 July 2025 | Jie Liu | <u>The safety and tolerance of PrEP among MSM in China: a prospective cohort study</u> |
| 14 July 2025 | Duygu Islek | <u>HIV pre-exposure prophylaxis continuum and reasons for never using pre-exposure prophylaxis among transfeminine persons in the United States: results from the Transgender Women's Internet Survey and Testing (TWIST)</u> |
| 14 July 2025 | Jason Mitchell | <u>Group by time analysis of decision making and working together for prevention and pleasure: outcomes from a digital HIV serostatus neutral intervention trial with adult, cisgender male couples</u> |
| 14 July 2025 | Laure Dupont-Benjamin | <u>Indirect treatment comparison of the efficacy of cabotegravir and lenacapavir for HIV pre-exposure prophylaxis (PrEP) versus no PrEP</u> |
| 14 July 2025 | Sally Itwi | <u>Survey focused promotion of injectable PrEP to enhance uptake of the service among adolescent girls and young women in a prospective cohort study in Lusaka, Zambia</u> |
| 14 July 2025 | Adedotun Ogunbajo | <u>Preferences for on-demand/intermittent/event-driven and long-acting injectable (LAI) HIV pre-exposure prophylaxis (PrEP) among HIV-negative Black gay, bisexual, and other sexual minority men in the United States: a qualitative study</u> |

Notable Presentations And Late-breaking Sessions

Pre-Exposure Prophylaxis, Long-Acting Agents, and Prevention (3/4)



| Date | Author | Title |
|--------------|------------------|---|
| 15 July 2025 | Aimee Metzner | <u>Real-world utilization and adherence of cabotegravir long-acting for HIV pre-exposure prophylaxis in the United States: results from the PrEPFACTS study using healthcare administrative claims data</u> |
| 15 July 2025 | Nyaradzo Mgodzi | <u>Acceptability and adherence to daily oral PrEP among adolescent girls and young women in sub-Saharan Africa: a randomized clinical trial comparing F/TAF and F/TDF</u> |
| 15 July 2025 | Carey Pike | <u>Characteristics of early non-persistors on Cabotegravir long-acting (injectable PrEP) compared to persistent users in the PrEPared to Choose study in Cape Town, South Africa</u> |
| 15 July 2025 | Brenda Kamusiime | <u>Women's preferences for embedding PrEP delivery within STI and reproductive health services in Uganda – results from a discrete choice experiment</u> |
| 16 July 2025 | Tapiwa Munthali | <u>Assisted partner notification as a strategy to enhance Pre-Exposure Prophylaxis (PrEP) screening and uptake – results from an urban STI clinic in Malawi</u> |
| 16 July 2025 | Maurice Musheke | <u>Community-based delivery of pre-exposure prophylaxis to adolescent girls and young women in the DREAMS Program in Zambia: an observational cohort study</u> |

Notable Presentations And Late-breaking Sessions

Pre-Exposure Prophylaxis, Long-Acting Agents, and Prevention (4/4)



| Date | Author | Title |
|--------------|------------------------------------|--|
| 16 July 2025 | Thiago SILVA TORRES | <u>PrEP Choice and Coverage among Young Sexual and Gender Minorities – Results from the ImPrEP CAB Brasil Study</u> |
| 16 July 2025 | Maria Cristina PIMENTA DE OLIVEIRA | <u>PrEP Choice and Preferences: Insights from the ImPrEP CAB-Brasil Study</u> |
| 16 July 2025 | Beatriz GRINSZTEJN | <u>The ImPrEP LEN Brasil Study Protocol</u> |
| 16 July 2025 | Keitumetse LEBELO | <u>Choices in motion: how young people in the PrEPared to Choose study (Cape Town, South Africa) navigate PrEP product switching</u> |
| 16 July 2025 | Rodenie OLETE | <u>PrEP awareness, willingness, and behavioral characteristics of men who have sex with men and transgender individuals in the Philippines: a latent class analysis of the PrEP-APPEAL study</u> |
| 17 July 2025 | Jane Kabami | <u>Peer-led PrEP/PEP strategy increases biomedical HIV prevention coverage among women who engage in sex work in Southwestern Uganda: the Peers for PrEP (P4P) Pilot Study</u> |
| 17 July 2025 | Cristina Pimenta | <u>Understanding preferences and transitioning between oral and injectable PrEP: insights from ImPrEP CAB Brasil Study</u> |



Notable Presentations And Late-breaking Sessions

Tuberculosis and HIV/TB Integration (1/2)

| Date | Author | Title |
|--------------|-----------------------------|--|
| 14 July 2025 | Huihua Zhang | <u>Performance of baseline hemoglobin in predicting incident tuberculosis among people with HIV: a longitudinal study</u> |
| 14 July 2025 | Alexandra Bitty-Anderson | <u>Diagnosing opportunistic infections among people with advanced HIV disease: results of a quasi-experimental study in Côte d'Ivoire</u> |
| 14 July 2025 | Noelle A. Benzekri | <u>Barriers to the diagnosis and treatment of tuberculosis in people with and without HIV in Abidjan, Côte d'Ivoire: a qualitative study</u> |
| 14 July 2025 | Elizabeth Kalema Nalintya | <u>A cluster randomized trial of visitect CD4 advanced disease platform among outpatients with advanced HIV disease in Uganda</u> |
| 14 July 2025 | Lebohang Makhosazana Mlambo | <u>Enhancing TB preventive treatment uptake among people living with HIV: insights from a qualitative study in South Africa</u> |
| 14 July 2025 | Andrew Agbo | <u>Assessing the effectiveness of community-based TB/HIV testing in improving TB/HIV case finding: case study in North-West Nigeria</u> |

Notable Presentations And Late-breaking Sessions

Tuberculosis and HIV/TB Integration (2/2)



| Date | Author | Title |
|--------------|-----------------|--|
| 15 July 2025 | Jayne Ellis | <u>Once-daily dolutegravir-based antiretroviral therapy amongst Ugandan adults with advanced HIV disease receiving 1-month of daily rifapentine and isoniazid for TB preventive therapy: results of a prospective pharmacokinetic cohort study</u> |
| 16 July 2025 | Jeronimo Mufume | <u>Lack of community-based TB and HIV integrated services as a potential factor for gaps in HIV testing among presumptive TB cases in Mozambique: a 3-year retrospective cohort study</u> |
| 17 July 2025 | Scott HEYSELL | <u>A two-by-two factorial randomized trial of immediate and/or sepsis-specific dose anti-tuberculosis therapy to improve mortality for adults with sepsis and HIV in East Africa</u> |
| 17 July 2025 | Felix GERBER | <u>Same-day antiretroviral therapy initiation in people with HIV and presumptive tuberculosis: a randomized, non-inferiority trial in Lesotho and Malawi (SaDAPT)</u> |
| 17 July 2025 | Vijay YELDANDI | <u>Predictors of recurrent tuberculosis among people living with HIV under routine ART care: an observational cohort study, Andhra Pradesh, India, 2024</u> |



Key Industry Sponsored Sessions Information

AIDS-IAS 2025 Key Industry Sponsored Sessions Information



| Date | Sponsor | Title |
|--------------|-----------------|---|
| 15 July 2025 | Gilead Sciences | The Power of Prevention |
| 15 July 2025 | Merck | The future of HIV prevention clinical trials |
| 17 July 2025 | Gilead Sciences | Pregnancy and long-acting ARVs for prevention and treatment |



Noteworthy AI / ML presentations at AIDS-IAS 2025





Themes from key AI / ML presentations at AIDS-IAS 2025 (1/4)

- **AI and machine learning are reshaping HIV care by enabling early risk prediction, improving diagnostics, accelerating drug discovery, and personalizing prevention and treatment, advancing precision health, and better outcomes.**
- Check out the key AI / ML themes at AIDS-IAS 2025 below:
- **Personalizing HIV Care with Machine Learning:**
 - Machine learning models in Nigeria and Haiti predicted ART interruptions, improving early intervention and retention among people living with HIV through personalized risk profiling
- **AI-Driven Risk Prediction for HIV Patients:**
 - ML algorithms identified ICU admission risk in HIV patients, enabling early triage and better allocation of intensive care resources in high-burden settings
- **Advanced Genomic Analysis Using BERT:**
 - BERT-based ML enhanced HIV sequence interpretation by accurately predicting genetic diversity and coreceptor usage, improving understanding of viral evolution and resistance



Themes from key AI / ML presentations at AIDS-IAS 2025 (2/4)

- **Accelerating Drug Discovery with Generative AI:**
 - Generative AI combined with structure-based design produced **novel HIV-1 reverse transcriptase inhibitors**, demonstrating high potency and therapeutic promise
- **AI Tools for TB Screening in PLHIV:**
 - AI-powered mobile chest X-rays deployed in Lagos **improved TB diagnosis among PLHIV**, enhancing screening accuracy in primary healthcare settings
- **Geospatial ML for HIV Hotspot Identification:**
 - Machine learning and geospatial clustering pinpointed HIV hotspots in Kenya, supporting precision targeting of testing and prevention services
- **Predictive Modeling for Black Women in Atlanta:**
 - A ML-based HIV risk model tailored for Black women in Atlanta improved risk prediction accuracy, supporting more focused prevention efforts.
- **AI-Enhanced HIV Program Management:**
 - AI assistants like MesoCare and RAG-based chatbots improved HIV program coordination by providing **real-time decision support and access to critical data**



Themes from key AI / ML presentations at AIDS-IAS 2025 (3/4)

- **Improving HIV Data Quality with Digital Platforms:**

- The e-first platform in Zimbabwe boosted the accuracy and timeliness of HIV prevention data, strengthening national health system performance

- **AI for Adolescent Mental Health Empowerment:**

- Tech interventions in Kenya improved mental health and ART/PrEP adherence among adolescents aged 15–24 through digital counseling and empowerment tools

- **AI-Supported HIV Self-Care Behaviors:**

- Behavioral insights from AI tools guided the development of HIV self-care interventions, improving motivation, autonomy, and health outcomes

- **Scaling PrEP Access via Digital Pathways:**

- AI-enabled platforms improved PrEP uptake by guiding users from digital awareness to service access in a streamlined, scalable model

- **Ethical AI Deployment in HIV Programs:**

- The Lancet Commission emphasized AI policy priorities, including ethical governance, data privacy, and equity in HIV service delivery



Themes from key AI / ML presentations at AIDS-IAS 2025 (4/4)

- **Building Local AI Capacity in Rwanda:**
 - Rwanda's national strategy focused on developing local AI skills and infrastructure to sustainably integrate digital health into HIV care
- **Trust and Community in AI Design:**
 - Community co-design emphasized transparency, language inclusivity, and control in AI companions for HIV prevention, building user trust and acceptability



Noteworthy AI / ML presentations at AIDS-IAS 2025

Notable presentations at AIDS-IAS 2025

AI/ ML (1/8)



| Date | Author | Title |
|--------------|----------------------------|--|
| 14 July 2025 | Sarah MORRIS | From potential to practice: Using AI to accelerate innovation in HIV and health systems in Africa |
| 14 July 2025 | Niket Patel | Leveraging BERT-based machine learning for HIV sequence analysis: insights into genetic diversity and coreceptor utilization |
| 14 July 2025 | Belkis Merve Akis Yildirim | Development and characterization of a novel HIV vaccine candidate using SpyTag/SpyCatcher technology to decorate virus-like particles displaying native-like Env trimers |
| 14 July 2025 | Damilola Bodun | Combining generative AI, machine learning, and structure-based drug design to develop potent HIV-1 reverse transcriptase inhibitors |
| 14 July 2025 | Jialu Li | Machine learning algorithms to predict the risk of admission to intensive care units in people living with HIV |
| 14 July 2025 | Chengyu Gao | Exploration of common molecular mechanisms and hub genes in diffuse large B cell lymphoma shared with AIDS using bioinformatics and machine learning strategies |



Notable presentations at AIDS-IAS 2025

AI/ ML (2/8)



| Date | Author | Title |
|--------------|-----------------------|--|
| 14 July 2025 | Jiaqin Wu | Predicting ART interruptions: a machine learning approach among PLHIV in Haiti |
| 14 July 2025 | Renauvat Mutarambirwa | Enhancing HIV and sexual reproductive health education through technology: lessons from the Tubimenye Platform in Musanze District high schools |
| 14 July 2025 | Lordlaro Lidoros | Leveraging technology in HIV prevention: the impact of WhatsApp chatbot in enhancing HIV awareness and prevention among Maseno university students |
| 14 July 2025 | Isaac Okello Opio | Predictors of internalising mental disorders among Ugandan children and adolescents living with HIV: a machine learning approach |
| 14 July 2025 | Wayne Otieno | Leveraging WhatsApp technology to enhance sexual offenses case reporting and justice delivery in Siaya county, Kenya |
| 14 July 2025 | Hildah Essendi | Impact of a technology-based intervention to advance mental health empowerment among adolescents and young people (AYP) aged 15-24 years and accessing ART and PrEP: a quasi-experimental study in Kenya |

Notable presentations at AIDS-IAS 2025

AI/ ML (3/8)



| Date | Author | Title |
|--------------|------------------|---|
| 14 July 2025 | Meredith Lora | Improving HIV risk assessment among Black women: A machine learning HIV prediction model in Atlanta, Georgia |
| 14 July 2025 | Joseph Ngugi | Enhancing HIV data and service quality assessments through mobile technology in Kenya (2021 - 2024) |
| 14 July 2025 | Dasha Ocheret | Exploration of scientific evidence and community perspectives on the role of artificial intelligence in Ending AIDS as a public health threat |
| 14 July 2025 | Brighton Kashiri | DHIS2 Android app improving data quality and service delivery of community health care services programs. Case study of DREAMS SMART program in Manicaland and Masvingo provinces of Zimbabwe |
| 14 July 2025 | Sendagala Ivan | MesoCare revolutionizing HIV care through AI-powered assistance |
| 14 July 2025 | Brian Bhole | Revolutionizing digital health: utilizing the courier logistics application for sustainable sample referral |



Notable presentations at AIDS-IAS 2025

AI/ ML (4/8)



| Date | Author | Title |
|--------------|---------------------|---|
| 14 July 2025 | Solomon Ssevvume | Implementation of HIV case-based surveillance using a centralized approach in Uganda |
| 14 July 2025 | Alinani Sikanyika | Enhancing access to high-quality sexual reproductive health services for adolescents and young people in Zambia through Tiko's tech-enabled trusted and verified results (TVR) approach |
| 14 July 2025 | Sandile Olivia Dube | Innovative approaches to monitoring CPD engagement for HIV education: insights from digital online CPD platform |
| 14 July 2025 | Diana Cherotin | Improving real-time reporting in the Electronic Case-Based TB Surveillance System at 155 health facilities in Bugisu and Bukedi regions using a quality improvement approach |
| 14 July 2025 | Edewell Mugariri | Efficiency of the electronic data management system in HIV prevention intervention: lessons from the e-first platform in selected districts of Zimbabwe, 2024 |
| 14 July 2025 | Uduak Akpan | Digital assistance tools improves timely access to tuberculosis preventive therapy: a retrospective cohort study in southern Nigeria |

Notable presentations at AIDS-IAS 2025

AI/ ML (5/8)



| Date | Author | Title |
|--------------|------------------|--|
| 14 July 2025 | Kennedy Muthoka | Using machine learning and geospatial clustering to identify hotspots for targeted HIV testing and prevention services in Kenya |
| 14 July 2025 | Khai Hoan Tram | Towards precision public health in HIV prevention: Leveraging smartphone GPS data to understand activity spaces for young adults in rural KwaZulu-Natal, South Africa |
| 15 July 2025 | Thobeka Mnguni | Using machine learning to personalize HIV care and reduce treatment interruptions for people living with HIV: results from an 11-month implementation study in Nigeria |
| 15 July 2025 | Patricia Khomani | A retrieval-augmented generation (RAG) AI Chatbot to improve HIV programme coordination and decision support |
| 15 July 2025 | Steven Karera | Leveraging social network analysis to support epidemiological research on HIV prevention and case management |
| 15 July 2025 | Kawina Paul Poho | Deployment of SmartCare Pro (EHR) with biometric functionality in 2024 to address HIV duplicate healthcare records in Zambia |



Notable presentations at AIDS-IAS 2025

AI/ ML (6/8)



| Date | Author | Title |
|--------------|-------------------|--|
| 15 July 2025 | Rory HENDERSON | Leveraging AI for vaccine design |
| 16 July 2025 | Sarah MORRIS | How can AI enable scale up and streamline delivery of long-acting prevention? |
| 16 July 2025 | Emeka Ezieke | Strengthening digital monitoring to scale up tuberculosis preventive treatment among new PLHIV in Akwa Ibom and Cross River States |
| 16 July 2025 | Athanase RUKUNDO | Re-tooling the Response: How Rwanda is Building Local AI Capacity for Health |
| 16 July 2025 | Jirair RATEVOSIAN | Navigating the Edge: AI, Risk, and Opportunity in Global Health |
| 16 July 2025 | Michael REID | The Lancet GH Commission on Artificial Intelligence and HIV: Priorities for Policy and Implementation |



Notable presentations at AIDS-IAS 2025

AI/ ML (7/8)



| Date | Author | Title |
|--------------|----------------------|---|
| 16 July 2025 | Rouella MENDONCA | Designing for Impact: Behavioral Insights from AI-Driven HIV Self-Care |
| 16 July 2025 | John Danvic ROSADIÑO | From Click to Care: Digital Pathways for Scalable PrEP Access |
| 16 July 2025 | Shawn MALONE | Integrating AI into HIV Care Pathways: Supporting Self-Care, Continuity, and Quality |
| 17 July 2025 | Clive Kafesu | Complementing community interventions with technology to maximize tracking of HIV exposed infants (HEI) final outcome, lessons from a community HIV program in Zimbabwe |
| 17 July 2025 | Mercy Nhamo-Murire | Harnessing technology to address HIV prevention, treatment, and unplanned pregnancies in Kenya, Uganda and South Africa |
| 17 July 2025 | Obioha UDUNZE | Innovative use of mobile digital chest-xray equipped with artificial intelligence to improve TB diagnosis among people living with HIV at primary health centres (PHCs) in Lagos, Nigeria |



Notable presentations at AIDS-IAS 2025

AI/ ML (8/8)



| Date | Author | Title |
|--------------|------------------|---|
| 17 July 2025 | Rouella MENDONCA | Building a safe, accurate AI companion: lessons from the Field |
| 17 July 2025 | Byrone CHINGOMBE | Co-designing trust: community voices in building an AI companion for HIV prevention |



Strategic Insights and Strategy Development is our focus

COMPETITIVE STRATEGY
AND INTELLIGENCE



DIGITAL HEALTH, ARTIFICIAL
INTELLIGENCE AND IoE



GENE & CELL THERAPY



VACCINES & INFECTIOUS
DISEASES



INVESTMENT INSIGHTS

e: INFO@LQVENTURES.COM

w: WWW.LQVENTURES.COM